These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 12464259)

  • 1. Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
    Baldwin A; Huang Z; Jounaidi Y; Waxman DJ
    Arch Biochem Biophys; 2003 Jan; 409(1):197-206. PubMed ID: 12464259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
    Lu H; Waxman DJ
    Mol Pharmacol; 2005 Jan; 67(1):212-9. PubMed ID: 15465924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
    Lu H; Chen CS; Waxman DJ
    Cancer Gene Ther; 2009 May; 16(5):393-404. PubMed ID: 19011599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Chen L; Waxman DJ
    Curr Pharm Des; 2002; 8(15):1405-16. PubMed ID: 12052216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes.
    Beulz-Riché D; Robert J; Riché C; Ratanasavanh D
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):274-80. PubMed ID: 11914905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes.
    Quintieri L; Geroni C; Fantin M; Battaglia R; Rosato A; Speed W; Zanovello P; Floreani M
    Clin Cancer Res; 2005 Feb; 11(4):1608-17. PubMed ID: 15746066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
    Jounaidi Y; Chen CS; Veal GJ; Waxman DJ
    Mol Cancer Ther; 2006 Mar; 5(3):541-55. PubMed ID: 16546968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
    Jounaidi Y; Hecht JE; Waxman DJ
    Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
    Huang Z; Raychowdhury MK; Waxman DJ
    Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol.
    Rainov NG; Dobberstein KU; Sena-Esteves M; Herrlinger U; Kramm CM; Philpot RM; Hilton J; Chiocca EA; Breakefield XO
    Hum Gene Ther; 1998 Jun; 9(9):1261-73. PubMed ID: 9650611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
    Chen L; Yu LJ; Waxman DJ
    Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
    Chen CS; Jounaidi Y; Waxman DJ
    Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs.
    Philip PA; Ali-Sadat S; Doehmer J; Kocarek T; Akhtar A; Lu H; Chan KK
    Cancer Chemother Pharmacol; 1999; 43(1):59-67. PubMed ID: 9923542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes.
    Weber GF; Waxman DJ
    Biochem Pharmacol; 1993 Apr; 45(8):1685-94. PubMed ID: 8484807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
    Chen L; Waxman DJ
    Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.
    Huang Z; Roy P; Waxman DJ
    Biochem Pharmacol; 2000 Apr; 59(8):961-72. PubMed ID: 10692561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.